共 58 条
[1]
Bayer R(2015)Public health in the precision-medicine era New England Journal of Medicine 373 499-501
[2]
Galea S(2017)PCSK9 inhibitors: a new era of lipid lowering therapy World Journal of Cardiology 9 76-1678
[3]
Chaudhary R(2014)Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO) Annals of Oncology 25 1673-1272
[4]
Garg J(2006)Sequence variations in PCSK9, low LDL, and protection against coronary heart disease New England Journal of Medicine 354 1264-1407
[5]
Shah N(2012)Investigating the potential for ethnic group harm in collaborative genomics research in Africa: is ethnic stigmatisation likely? Social Science & Medicine 75 1400-694
[6]
Sumner A(2018)Identity inference of genomic data using long-range familial searches Science 362 690-659
[7]
Ciardiello F(2015)Precision medicine: at what price? American Journal of Respiratory and Critical Care Medicine 192 658-642
[8]
Arnold D(2012)Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research Genetics in Medicine 14 633-399
[9]
Casali PG(2015)GINA, genetic discrimination, and genomic medicine New England Journal of Medicine 372 397-2219
[10]
Cervantes A(2017)Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing Circulation 136 2210-1041